743 Results

People

  1. Zelenetz
    Zelenetz
  2. Moskowitz
    Moskowitz
  3. Noy
    Noy
  4. Horwitz
    Horwitz
  5. Hamlin
    Hamlin
  6. Palomba
    Palomba
  7. Matasar
    Matasar
  8. Portlock
    Portlock
  9. Moskowitz
    Moskowitz
  10. Yahalom
    Yahalom

Groups

  1. Center for Hematologic Malignancies (743)
  2. Department of Medicine (743)
  3. Hematologic Malignancies, Division of (743)
  4. Lymphoma (743)
  5. Survivorship Research (218)
  6. Population Sciences Research Program (168)
  7. Epidemiology and Biostatistics (143)
  8. Biostatistics Service (122)
  9. Radiation Oncology, Department of (110)
  10. Executive Committee, Center for Hematologic Malignancies (105)
  1. "Center for Hematologic Malignancies"
  2. "Andrew Zelenetz"
Formats
  1. Meeting Abstract (436)
  2. Journal Article (278)
  3. Research Letter (10)
  4. Book Section (7)
  5. Guidelines (4)
  6. Conference Paper (3)
  7. Editorial (3)
  8. Correspondence (1)
  9. Review (1)
Groups
  1. Center for Hematologic Malignancies (743)
  2. Department of Medicine (743)
  3. Hematologic Malignancies, Division of (743)
  4. Lymphoma (743)
  5. Survivorship Research (218)
  6. Population Sciences Research Program (168)

More Groups

People
  1. Andrew Zelenetz (743)
  2. Craig Moskowitz (206)
  3. Ariela Noy (165)
  4. Paul Hamlin (162)
  5. David Straus (158)
  6. Steven Horwitz (150)

More People

Years
  1. 2024 (4)
  2. 2023 (36)
  3. 2022 (30)
  4. 2021 (29)
  5. 2020 (32)
  6. 2019 (39)

More Years

Publications
  1. Blood (303)
  2. Journal of Clinical Oncology (82)
  3. Journal of the National Comprehensive Cancer Network (35)
  4. British Journal of Haematology (32)
  5. Leukemia and Lymphoma (28)
  6. Annals of Oncology (26)

More Publications

Publishers
  1. American Society of Hematology (314)
  2. American Society of Clinical Oncology (84)
  3. John Wiley & Sons (39)
  4. Harborside Press (35)
  5. Oxford University Press (31)
  6. Elsevier Inc. (30)

More Publishers

Results (743)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Gemcitabine plus pembrolizumab after checkpoint blockade failure as a strategy in multiply relapsed Hodgkin lymphoma
    Research Letter

    Stuver, R.; Noy, A.; Vardhana, S. A.; Zelenetz, A. D.; Moskowitz, A. J.
    British Journal of Haematology (2024)

    Fulltext@MSK | Save
  • Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1/3 degrader NX-2127
    Journal Article

    Montoya, S.; Bourcier, J.; Noviski, M.; Lu, H.; Thompson, M. C.; Chirino, A.; Jahn, J.; Sondhi, A. K.; Gajewski, S.; Tan, Y. S.; more...
    Science (2024)

    Fulltext@MSK | Save
  • Phase I study of bendamustine, rituximab, ibrutinib, and venetoclax in relapsed, refractory mantle cell lymphoma
    Journal Article

    Grieve, C.; Joseph, A.; Drullinsky, P.; Zelenetz, A. D.; Hamlin, P.; Kumar, A.
    Leukemia and Lymphoma (2024)

    Fulltext@MSK | Save
  • Diffuse large B-cell lymphoma involving osseous sites: Utility of response assessment by PET/CT and good long-term outcomes
    Journal Article

    Ghione, P.; Ahsanuddin, S.; Luttwak, E.; Varela, S. B.; Nakajima, R.; Michaud, L.; Gupta, K.; Navitski, A.; Straus, D.; Palomba, M. L.; more...
    Haematologica (2024)

    Fulltext@MSK | Save
  • Infectious complications in patients with relapsed or refractory (R/R) Non-Hodgkin's lymphoma (NHL) treated with the anti-CD20xCD3 bispecific antibody (BsAb) mosunetuzumab
    Meeting Abstract

    Shahid, Z.; Okwali, M.; Joseph, A.; Seo, S. K.; Lue, J. K.; Boardman, A. P.; Caron, P.; David, K. A.; Epstein-Peterson, Z. D.; Ghione, P.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Real-world outcomes in patients with transformed follicular lymphoma treated with CD19-targeting CAR-T therapy
    Meeting Abstract

    Rivas-Delgado, A.; Luttwak, E.; Drill, E.; Goldstein, I.; Landego, I.; Tomas, A. A.; Parascondola, A.; Saldia, A.; Caron, P.; Dahi, P. B.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Clinical characteristics and outcomes of limited stage high grade B-cell lymphoma with MYC/BCL2 and/or BCL6 rearrangements: A single center experience
    Meeting Abstract

    Lue, J. K.; Luttwak, E.; Caron, P.; Boardman, A. P.; David, K. A.; Rivas-Delgado, A.; Epstein-Peterson, Z. D.; Falchi, L.; Ghione, P.; Hamlin, P. A.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Brentuximab vedotin-based regimens for older patients with newly diagnosed classical Hodgkin lymphoma -Real world experience
    Meeting Abstract

    Luttwak, E.; Ganesan, N.; Boardman, A. P.; Caron, P.; David, K. A.; Rivas-Delgado, A.; Falchi, L.; Ghione, P.; Hamlin, P. A.; Horwitz, S. M.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Potent CD8+T-cell proliferation and effector differentiation following subcutaneous (SC) mosunetuzumab administration in patients with untreated, high tumor-burden follicular lymphoma (FL)
    Meeting Abstract

    Falchi, L.; Lin, Y. H.; Melendez, L.; Ghione, P.; Owens, C.; Hamlin, P. A.; Lue, J. K.; Epstein-Peterson, Z. D.; Kumar, A.; Palomba, M. L.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Pirtobrutinib in relapsed/refractory (R/R) mantle cell lymphoma (MCL) patients with prior cBTKi: Safety and efficacy including high-risk subgroup analyses from the phase 1/2 BRUIN study
    Meeting Abstract

    Cohen, J. B.; Shah, N. N.; Jurczak, W.; Zinzani, P. L.; Cheah, C. Y.; Eyre, T. A.; Ujjani, C. S.; Koh, Y.; Kim, W. S.; Nasta, S. D.; more...
    Blood (2023)

    Fulltext@MSK | Save